$DOVA News
Last published 5y ago
- 5y agoDOVAIstari Oncology Hires Marc Banjak as General Counsel and Secretary as the Company Prepares for a Critical Period of Development and ExpansionBusiness WireIstari Oncology, Inc., a clinical-stage biotechnology company today announced that Marc Banjak has joined the company as general counsel and secretary. Mr. Banjak comes to Istari from Dova Pharmaceuticals (NASDAQ:DOVA), where he led the legal and compli
- 7y agoDOVASobi Successfully Completes Acquisition of Dova PharmaceuticalsPR NewswireSwedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Dova Pharmaceuticals, Inc. (Dova) (NASDAQ: DOVA) announced today the completion of the...
- 7y agoDOVASobi Successfully Completes Tender Offer for All Outstanding Shares of Dova PharmaceuticalsPR NewswireSwedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) announced today that its indirect wholly owned subsidiary Dragonfly Acquisition Corp....
- 7y agoMCRNEEIPVTLDOVAMoore Kuehn, PLLC Encourages Milacron Holdings Corp. (MCRN), Ecology & Environmental, Inc. (EEI), Pivotal Software, Inc. (PVTL), and Dova Pharmaceuticals, Inc. (DOVA) Investors to Contact FirmPR NewswireMoore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims involving the directors...
- 7y agoDOVASobi to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in HaematologyPR NewswireSwedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) today announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by...
- 7y agoDOVADova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi)GlobeNewswireConsideration of up to $29.00 per share includes $27.50 per share in upfront cash and an additional $1.50 per share upon regulatory approval of DOPTELET® for chemotherapy-induced thrombocytopenia...
- 7y agoDOVADova Pharmaceuticals to Present at 2019 Cantor Global Healthcare ConferenceGlobeNewswireDURHAM, N.C., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019...
- 7y agoDOVADova Pharmaceuticals, Inc. (DOVA) CEO David Zaccardelli on Q2 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 7y agoDOVADova Pharmaceuticals' (DOVA) CEO David Zaccardelli on Q4 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoDOVADova Pharmaceuticals' (DOVA) CEO Alex Sapir on Q1 2018 Results - Earnings Call TranscriptEarnings Call Transcripts